Overview

A Study of LY2835219 in Healthy Participants

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days apart. One dose will be given with a standard meal, one dose with a high-fat meal and one dose without food. The study will evaluate the effects of the standard and high-fat meals on how much drug gets into the bloodstream. Side effects will be documented. This study is approximately 43 days, not including screening. Screening is required within 28 days prior to the start of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company